FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2803209898> ?p ?o ?g. }

• W2803209898 endingPage "5428" @default.
• W2803209898 startingPage "5428" @default.
• W2803209898 abstract "Abstract Introduction: Chronic myeloid leukemia (CML) is characterized by the t(9:22) translocation known as the Philadelphia chromosome (Ph). Although ABL tyrosine kinase inhibitors (ABL TKI) such as imatinib, dasatinib and nilotinib have improved CML treatment, such therapies cannot cure patients with Philadelphia chromosome (Ph)-positive leukemia because of leukemia stem cells. Moreover, some patients develop BCR-ABL point mutations including T315I and become resistant to ABL TKI therapy. These leukemia stem cells are contained within a niche in the bone marrow and are often impervious to current treatments. Therefore, new approach against BCR-ABL mutant cells and LSCs may improve the outcome of Ph-positive leukemia patients. B cell lymphoma 2 (BCL-2) protein families are key regulator of apoptosis and highly promising targets for the development of anti-cancer treatment. Venetoclax, also known as ABT-199 is a selective, orally bioavailable BCL-2 inhibitor. Venetoclax is investigated in a pivotal phase 3 clinical trial against hematological malignancies such as chronic lymphocytic leukemia (CLL) and approved for the treatment of patients with CLL. Materials and methods: In this study, we investigated whether venetoclax could suppress Ph-positive leukemia cells including T315I mutation and primary samples. Results: BCL-2 expression was found in Ph-positive leukemia cells including primary samples, however, BCL-2 expression was reduced in K562 cells. We found 72 h venetoclax treatment inhibited the growth of Ba/F3 BCR-ABL and KCL-22 cells in a dose dependent manner. However, venetoclax activity was reduced in K562 cells. We examined the intracellular signaling after treatment of venetoclax. Phosphorylation of BCR-ABL and Crk-L was not reduced. However, activity of caspase 3, poly (ADP-ribose) polymerase (PARP) was increased. We next investigated the efficacy between ABL TKI and venetoclax by using these cell line. Combined treatment of Ba/F3 BCR-ABL cells with imatinib and venetoclax caused significantly more cytotoxicity than each drug alone. Apoptotic cells were also increased. Phosphorylation of BCR-ABL, Crk-L was reduced and cleaved caspase 3 and PARP activity was increased after imatinib and venetoclax treatment. We investigated the venetoclax activity against T315I positive cells. Venetoclax potently induced cell growth inhibition of Ba/F3 T315I mutant cells in a dose dependent manner. Combined treatment of Ba/F3 T315I mutant cells with ponatinib and venetoclax caused significantly more cytotoxicity than each drug alone. Apoptotic cells were also increased. Phosphorylation of BCR-ABL, Crk-L was reduced and cleaved PARP was increased after ponatinib and venetoclax treatment. To assess the activity of ponatinib and venetoclax, we examined tumor formation in mice model. We injected subcutaneously 1×107 Ba/F3 T315I mutant cells in nude mice. A dose of 20 mg/kg/day p.o of ponatinib and 50 mg/kg/day p.o of venetoclax inhibited tumor growth and reduced tumor volume compared with control mice. In the immunohistochemical analysis, we found that tumors in mice treated with ponatinib and venetoclax exhibited an increase in apoptotic cells. We also found that co-treatment with ponatinib and venetoclax increased mouse survival. The treatments were well tolerated with no animal health concerns observed. We also found that the treatment of venetoclax exhibits cell growth inhibition against CD34 positive CML samples. Conclusion: The results of our study indicate that the BCL-2 inhibitor venetoclax may be a powerful strategy against ABL TKI resistant cells including T315I mutation and enhance cytotoxic effects of ABL TKI against those Ph-positive leukemia cells. Disclosures Tauchi: Pfizer Inc.: Research Funding. Ohyashiki:Novartis International AG,: Honoraria, Research Funding; Bristol-Myers Squibb: Research Funding." @default.
• W2803209898 created "2018-06-01" @default.
• W2803209898 creator A5016402296 @default.
• W2803209898 creator A5053689963 @default.
• W2803209898 creator A5054243155 @default.
• W2803209898 creator A5083522292 @default.
• W2803209898 date "2016-12-02" @default.
• W2803209898 modified "2023-09-27" @default.
• W2803209898 title "Anti-Leukemic Effects of Venetoclax on Philadelphia Chromosome Positive Leukemia Cells" @default.
• W2803209898 doi "https://doi.org/10.1182/blood.v128.22.5428.5428" @default.
• W2803209898 hasPublicationYear "2016" @default.
• W2803209898 type Work @default.
• W2803209898 sameAs 2803209898 @default.
• W2803209898 citedByCount "6" @default.
• W2803209898 countsByYear W28032098982019 @default.
• W2803209898 countsByYear W28032098982020 @default.
• W2803209898 countsByYear W28032098982021 @default.
• W2803209898 countsByYear W28032098982023 @default.
• W2803209898 crossrefType "journal-article" @default.
• W2803209898 hasAuthorship W2803209898A5016402296 @default.
• W2803209898 hasAuthorship W2803209898A5053689963 @default.
• W2803209898 hasAuthorship W2803209898A5054243155 @default.
• W2803209898 hasAuthorship W2803209898A5083522292 @default.
• W2803209898 hasConcept C104317684 @default.
• W2803209898 hasConcept C138626823 @default.
• W2803209898 hasConcept C171122931 @default.
• W2803209898 hasConcept C203014093 @default.
• W2803209898 hasConcept C2776960273 @default.
• W2803209898 hasConcept C2777413986 @default.
• W2803209898 hasConcept C2777583451 @default.
• W2803209898 hasConcept C2777938653 @default.
• W2803209898 hasConcept C2778461978 @default.
• W2803209898 hasConcept C2778729363 @default.
• W2803209898 hasConcept C2778904597 @default.
• W2803209898 hasConcept C2779536868 @default.
• W2803209898 hasConcept C2779675984 @default.
• W2803209898 hasConcept C3019892230 @default.
• W2803209898 hasConcept C502942594 @default.
• W2803209898 hasConcept C54355233 @default.
• W2803209898 hasConcept C71924100 @default.
• W2803209898 hasConcept C86803240 @default.
• W2803209898 hasConceptScore W2803209898C104317684 @default.
• W2803209898 hasConceptScore W2803209898C138626823 @default.
• W2803209898 hasConceptScore W2803209898C171122931 @default.
• W2803209898 hasConceptScore W2803209898C203014093 @default.
• W2803209898 hasConceptScore W2803209898C2776960273 @default.
• W2803209898 hasConceptScore W2803209898C2777413986 @default.
• W2803209898 hasConceptScore W2803209898C2777583451 @default.
• W2803209898 hasConceptScore W2803209898C2777938653 @default.
• W2803209898 hasConceptScore W2803209898C2778461978 @default.
• W2803209898 hasConceptScore W2803209898C2778729363 @default.
• W2803209898 hasConceptScore W2803209898C2778904597 @default.
• W2803209898 hasConceptScore W2803209898C2779536868 @default.
• W2803209898 hasConceptScore W2803209898C2779675984 @default.
• W2803209898 hasConceptScore W2803209898C3019892230 @default.
• W2803209898 hasConceptScore W2803209898C502942594 @default.
• W2803209898 hasConceptScore W2803209898C54355233 @default.
• W2803209898 hasConceptScore W2803209898C71924100 @default.
• W2803209898 hasConceptScore W2803209898C86803240 @default.
• W2803209898 hasIssue "22" @default.
• W2803209898 hasLocation W28032098981 @default.
• W2803209898 hasOpenAccess W2803209898 @default.
• W2803209898 hasPrimaryLocation W28032098981 @default.
• W2803209898 hasRelatedWork W2088110060 @default.
• W2803209898 hasRelatedWork W2155107050 @default.
• W2803209898 hasRelatedWork W2306349432 @default.
• W2803209898 hasRelatedWork W2387857109 @default.
• W2803209898 hasRelatedWork W2532947472 @default.
• W2803209898 hasRelatedWork W2551572632 @default.
• W2803209898 hasRelatedWork W2552820660 @default.
• W2803209898 hasRelatedWork W2751676438 @default.
• W2803209898 hasRelatedWork W2803209898 @default.
• W2803209898 hasRelatedWork W2983751648 @default.
• W2803209898 hasVolume "128" @default.
• W2803209898 isParatext "false" @default.
• W2803209898 isRetracted "false" @default.
• W2803209898 magId "2803209898" @default.
• W2803209898 workType "article" @default.